Evidence map›Paper›PMID 39545731›Full record

ReviewClinical microbiology reviews2024

Laboratory detection of carbapenemases among Gram-negative organisms.

Patricia J Simner, Johann D D Pitout, Tanis C Dingle

Abstract readReview
In one paragraph

Review in Clinical microbiology reviews, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline for antimicrobial treatment of multidrug-resistant Gram-negative infections: practice recommendations of the Brazilian Society of Infectious Diseases.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Guideline
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Aztreonam plus ceftazidime/avibactam broth disk elution test: failure to detect Escherichia coli with PBP-3 insertions.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Breathe (Sheffield, England) · 2026
    Review
  13. Article
  14. Article
  15. Article
  16. Rapid commercial CTX-M diagnostics: Performance, limitations and clinical impact.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Review
  17. Molecular Insights into Carbapenem Resistance inInternational journal of molecular sciences · 2026
    Review
  18. Article
  19. CRISPR/Cas diagnostics forFrontiers in bioengineering and biotechnology · 2026
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Patricia J SimnerDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-6134-151X
Johann D D PitoutCummings School of Medicine, University of Calgary, Calgary, Calgary, Alberta, Canada.ORCID 0000-0002-4547-4707
Tanis C DingleCummings School of Medicine, University of Calgary, Calgary, Calgary, Alberta, Canada.ORCID 0000-0002-6936-406X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SUMMARYThe carbapenems remain some of the most effective options available for treating patients with serious infections due to Gram-negative bacteria. Carbapenemases are enzymes that hydrolyze carbapenems and are the primary method driving carbapenem resistance globally. Detection of carbapenemases is required for patient management, the rapid implementation of infection prevention and control (IP&C) protocols, and for epidemiologic purposes. Therefore, clinical and public health microbiology laboratories must be able to detect and report carbapenemases among predominant Gram-negative organisms from both cultured isolates and direct from clinical specimens for treatment and surveillance purposes. There is not a "one size fits all" laboratory approach for the detection of bacteria with carbapenemases, and institutions need to determine what fits best with the goals of their antimicrobial stewardship and IP&C programs. Luckily, there are several options and approaches available for clinical laboratories to choose methods that best suits their individual needs. A laboratory approach to detect carbapenemases among bacterial isolates consists of two steps, namely a screening process (

Indexed as

Bacterial Proteinsbeta-LactamasesGram-Negative BacteriaGram-Negative Bacterial InfectionsAnti-Bacterial AgentsCarbapenemsDrug Resistance, BacterialHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasescarbapenemaseCarbapenemsAcinetobacter baumannii complexcarbapenemasecarbapenem resistanceEnterobacteralesGram-negative bacterialaboratory detectionmethodsPseudomonas aeruginosa

Identifiers

PMID39545731
PMCPMC11629623

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.